Drug intelligence / Profile preview

GL-SRF-003 (GILongevity)

Development stage: Preclinical
Lead developer: GI Innovation
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

GL-SRF-003 is an investigational recombinant fusion protein being developed by GILongevity, a subsidiary of GI Innovation, for the dual indication of skin and hair regeneration. Developed using the company's proprietary protein engineering platform, the asset is designed to promote tissue repair and stimulate hair follicle growth. It is currently in the discovery and preclinical stage of development, targeting biological pathways involved in cellular rejuvenation and the hair growth cycle.

Beyond the preview

Go deeper on GL-SRF-003 (GILongevity).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GL-SRF-003 (GILongevity).

Explore the full profile